Xigris Breaking News

Xigris is supposed to treat sepsis, but it does no more than a placebo, with severe side effects. Keep up to date with Xigris and Eli Lilly with the following news articles. If you or a loved one has suffered due to Xigris, fill out this simple form for a free, non-obligitory case review within 24 hours.

Study: Lilly's Xigris didn't help patients with mild sepsis

September 29, 2005 (indystar.com)

Indianapolis (Bloomberg) -- Eli Lilly and Co.'s Xigris failed to benefit patients with mild cases of sepsis, a potentially fatal blood infection, a company-funded study found.

The Food and Drug Administration approved Xigris for marketing in 2001 based on a study showing the drug reduced death rates from severe forms of sepsis. The agency restricted Xigris' use to the highest-risk patients and asked Lilly to conduct additional research to see if it helped patients with milder forms of the condition.

Study Rules Out Xigris in Low Death-Risk Sepsis Patients

September 28th, 2005 (medpagetoday.com)

DENVER, Sept. 28-Xigris (drotrecogin alfa, activated) should not be used in patients with severe sepsis but a low risk of death, researchers have concluded. A large, prospective, randomized, placebo-controlled Phase 4 trial of Xigris was stopped early because there was no evidence of a beneficial effect and there was an increased incidence of serious bleeding complications among patients receiving the drug, said Edward Abraham, M.D., of the University of Colorado Health Sciences Center here.

Weitz & Luxenberg is no longer accepting new Xigris cases.

see also:

Breaking News Eli Lilly's Xigris Lawsuit Reseach Center: Xigris Breaking News
Xigris Lawsuit Research: Eli Lilly's Xigris Breaking News provided by Xigris Lawyers

News & Warnings Xigris Lawsuit Reseach Center: Xigris News & Warnings
Xigris Lawsuit Research: Xigris News & Warnings provided by Xigris Lawyers